Drug profile · INN
orlistat
XENICAL
orlistat (XENICAL) is a pancreatic lipase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — orlistat
- US status
- approved
- Class
- Alimentary tract and metabolism (A08)
- Route
- ORAL
- Patents
- 20
- Programs
- 30
- Data quality
- 0.84
Quick answer
orlistat (XENICAL) is a pancreatic lipase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Pancreatic lipase inhibitor
Primary target: Gastric triacylglycerol lipase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2026047020
FORMES CRISTALLINES D'INHIBITEURS DE HER2/MUTEGFR ET LEUR PROCÉDÉ DE PRÉPARATION
granted -
WO 2026047022
FORME POSOLOGIQUE PHARMACEUTIQUE SOLIDE ET STABLE COMPRENANT UNE FORME CRISTALLINE D'UN INHIBITEUR DE HER2/MUTEGFR ET SA MÉTHODE DE PRÉPARATION
granted -
WO 2025242585
FORMES CRISTALLINES DE SELS D'ÉLINZANÉTANT ET COMPOSITIONS CONTENANT DES SELS D'ÉLINZANÉTANT
granted -
US 12410184
Crystalline forms of a menin inhibitor
granted -
US 12384854
Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
granted -
US 12378245
Crystalline forms of an RSK inhibitor
granted -
US 12344585
Crystalline salts of a plasma kallikrein inhibitor
granted -
US 12338249
Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea
granted -
US 12329805
Dosage forms of tissue kallikrein 1
granted -
US 12319693
Crystalline forms of CFTR modulators
granted -
US 12319657
Solid state crystalline forms of a selective potassium channel modulator
granted -
US 12319651
Crystalline forms and methods of producing crystalline forms of a compound
granted -
US 12286431
Crystalline forms of a KRas G12C inhibitor
granted -
US 12281136
Crystalline forms of a CD73 inhibitor and uses thereof
granted -
US 12281113
Crystalline forms of a KRas G12C inhibitor
granted -
US 12239638
Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
granted -
US 12240918
Bispecific antibodies against plasma kallikrein and factor XII
granted -
US 12221441
Plasma kallikrein inhibitors and uses thereof
granted -
US 12187698
Crystalline forms of C21H22Cl2N4O2
granted -
US 12162838
Human plasma kallikrein inhibitors
granted
Frequently asked questions
What is orlistat?
orlistat (XENICAL) is a pancreatic lipase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for orlistat?
XENICAL is a marketed brand name for orlistat. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of orlistat?
orlistat has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.